North America Next-generation Antibody Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)

No. of Pages: 132    |    Report Code: TIPRE00028002    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Next-generation Antibody Market

1.           Introduction

1.1         Study Scope

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Next-generation Antibody Market – By Therapeutic Area

1.3.2        North America Next-generation Antibody Market – By Technology

1.3.3        North America Next-generation Antibody Market – By Country

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Next-generation Antibody Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        North America PEST Analysis

4.3         Experts Opinion

5.           Next-generation Antibody Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing Prevalence of Cancer

5.1.2        Growing Demand for Next-Generation Antibody Therapeutics

5.2         Market Restraints

5.2.1        Complications Associated with Manufacturing and Approvals

5.3         Future Trends

5.3.1        Developments in Next-Generation Antibodies

5.4         Impact Analysis

6.           Next-generation Antibody Market–North America Analysis

6.1         North America Next-generation Antibody Market Revenue Forecast and Analysis

7.           North America Next-generation Antibody Market Revenue and Forecasts To 2028– by Therapeutic Area

7.1         Overview

7.2         North America Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)

7.3         Oncology

7.3.1        Overview

7.3.2        Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

7.4         Autoimmune or Inflammatory

7.4.1        Overview

7.4.2        Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

8.           Next-generation Antibody Market Revenue and Forecasts To 2028 – Technology

8.1         Overview

8.2         Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)

8.3         Antibody-drug conjugates

8.3.1        Overview

8.3.2        Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.4         Bispecific antibodies

8.4.1        Overview

8.4.2        Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.5         Fc engineered antibodies

8.5.1        Overview

8.5.2        Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.6         Antibody fragments and antibody-like proteins

8.6.1        Overview

8.6.2        Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.7         Biosimilar antibody products

8.7.1        Overview

8.7.2        Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

9.           North America Next-generation Antibody Market Revenue and Forecasts to 2028 – Country Analysis

9.1         North America: Next-generation Antibody Market

9.1.1        Overview

9.1.2        North America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.3        North America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.4        North America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5        North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)

9.1.5.1          US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.1          Overview

9.1.5.1.2          US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.3          US: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.1.4          US: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5.2          Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.1          Overview

9.1.5.2.2          Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.3          Canada: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.2.4          Canada: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5.3          Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.1          Overview

9.1.5.3.2          Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.3          Mexico: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.3.4          Mexico: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

10.        Impact Of COVID-19 Pandemic on Next-generation Antibody Market

10.1      North America: Impact Assessment of COVID-19 Pandemic

11.        Next-generation Antibody Market–Industry Landscape

11.1      Overview

11.2      Organic Developments

11.2.1     Overview

11.3      Inorganic Developments

11.3.1     Overview

12.        Company Profiles

12.1      F. HOFFMANN-LA ROCHE LTD.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Kyowa Kirin Co., Ltd.

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Seagen Inc.

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      ImmunoGen, Inc.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      Takeda Pharmaceutical Company Limited

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Amgen Inc.

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Pfizer Inc.

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8      Catalent Inc

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9      AstraZeneca

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

12.10   Xencor

12.10.1  Key Facts

12.10.2  Business Description

12.10.3  Products and Services

12.10.4  Financial Overview

12.10.5  SWOT Analysis

12.10.6  Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             New Cancer Cases Registered Worldwide, 2020

Table 2.             North America Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 3.             North America Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 4.             US Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 6.             Canada: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Canada Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 8.             Mexico: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Mexico Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 10.          Organic Developments in the Next-generation Antibody Market

Table 11.          Inorganic Developments in the Next-generation Antibody Market

Table 12.          Glossary of Terms

 


LIST OF FIGURES

Figure 1.           Next-generation Antibody Market Segmentation

Figure 2.           Next-generation Antibody Market, By Country

Figure 3.           North America Next-generation Antibody Market Overview

Figure 4.           Oncology Segment Held Largest Share of Therapeutic Area Segment in Next-generation Antibody Market

Figure 5.           North America Next-generation Antibody Market- Leading Country Markets (US$ Million)

Figure 6.           North America: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Next-Generation Antibody Market Impact Analysis of Driver and Restraints

Figure 9.           North America Next-generation Antibody Market– Revenue Forecast and Analysis – 2021 - 2028

Figure 10.        North America Next-generation Antibody Market, by Therapeutic Area, 2021 & 2028 (%)

Figure 11.        Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)

Figure 14.        Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)

Figure 15.        Bispecific antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)

Figure 16.        Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)

Figure 17.        Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)

Figure 18.        Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)

Figure 19.        North America: Next-generation Antibody Market, by Key Country – Revenue (2021) (US$ Million)

Figure 20.        North America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

Figure 21.        North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)

Figure 22.        US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Impact of COVID-19 Pandemic in North American Country Markets

 

 

The List of Companies - North America Next-generation Antibody Market

  1. F. HOFFMANN-LA ROCHE LTD.
  2. Kyowa Kirin Co., Ltd.
  3. Seagen Inc.
  4. ImmunoGen, Inc.
  5. Takeda Pharmaceutical Company Limited
  6. Amgen Inc.
  7. Pfizer Inc.
  8. Catalent Inc
  9. AstraZeneca
  10. Xencor